Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOST | Q9BQB4 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5501263 | 0.86 | RAB9A (0.33) | CHRNA7 | |
| SCHEMBL17057328 | 0.86 | RAB9A (0.33) | CHRNA7 | |
| SCHEMBL25355436 | 0.79 | CHRNB2 (0.38) | CHRNA7 | |
| SCHEMBL1427279 | 0.78 | CHRNA7 (0.33) | CHRNA7HTR3A | |
| SCHEMBL17305971 | 0.78 | SOST (0.34) | SOST | |
| SCHEMBL20738588 | 0.78 | SOST (0.37) | SOSTCHRNA7 | |
| Hydrochloric Acid SCHEMBL3997316 | 0.76 | CHRNA7 (0.32) | CHRNA7HTR3A | |
| SCHEMBL16490229 | 0.73 | CHRNB2 (0.39) | SOSTCHRNA7 | |
| SCHEMBL6530407 | 0.73 | MCOLN3 (0.38) | — | |
| SCHEMBL14454560 | 0.73 | RIPK1 (0.39) | SOST |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3638658-B1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-10-08 | — | — | EP | claimed |
| US-7371748-B2 | Benzothiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | claimed |
| EP-1636223-B1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | claimed |
| EP-1455792-B1 | UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | claimed |
| US-20040235915-A1 | Benzothiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | US | claimed |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | FLOHR ALEXANDER (CH) | 2004-11-18 | — | — | US | claimed |
| US-6727247-B2 | ADENOSINE RECEPTOR LIGANDS IN A METHOD OF TREATMENT, CONTROL, OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMAN-LA ROCHE INC. | 2004-04-27 | — | — | US | claimed |
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. | 2003-08-07 | — | — | US | claimed |
| WO-2024215862-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| CN-112105621-B | Optically active bridged cyclic secondary amine derivatives | 住友制药株式会社 | 2024-02-20 | — | — | CN | disclosed |
| CN-112771055-B | Optically active bridged piperidine derivatives | 住友制药株式会社 | 2023-10-20 | — | — | CN | disclosed |
| CN-112585140-B | Optically active azabicyclo derivatives | 住友制药株式会社 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| EP-1636223-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. Hoffman-la Roche AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005000842-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040235915-A1 | Benzothiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | US | disclosed |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | FLOHR ALEXANDER (CH) | 2004-11-18 | — | — | US | disclosed |
| US-6727247-B2 | ADENOSINE RECEPTOR LIGANDS IN A METHOD OF TREATMENT, CONTROL, OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMAN-LA ROCHE INC. | 2004-04-27 | — | — | US | disclosed |
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | HOFFMAN-LA ROCHE INC. | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149036-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | SOST 3751/4885CHRNA7 677/4885HTR3A 262/4885 |
| US-20040235915-A1 | Benzothiazole derivatives | ADORA1, ADORA2A, ADORA3 | SOST 4338/4885CHRNA7 92/4885HTR3A 22/4885 |
| US-20040229893-A1 | Substituted benzothiazole amide derivatives | ADORA2A, ADORA1, ADORA2B | SOST 3751/4885CHRNA7 677/4885HTR3A 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.